Adherence‑Focused Glycemic Management in Older Adults with Type 2 Diabetes

1. Adherence and Dosing Strategies

Twice‑daily dosing of immediate‑release metformin creates a significant adherence barrier in older adults with complex medication regimens, reducing the likelihood of achieving glycemic targets. [American Diabetes Association] [1][2]
Metformin extended‑release (ER) formulations enable once‑daily dosing, which substantially improves medication adherence and lowers the risk of missed doses. [American Diabetes Association] 1
Regimen simplification is a priority for older adults to reduce treatment burden and improve adherence. [American Diabetes Association] [4][5]6

For a generally healthy 78‑year‑old patient, an A1C target of < 7.5 %– 8.0 % is reasonable and balances benefits with risks. [American Diabetes Association] [4][5]6
An current A1C of 7.9 % lies only 0.4 %– 0.9 % above this individualized target, indicating that aggressive intensification is often unnecessary. [American Diabetes Association] [4][5]
Avoiding hypoglycemia and minimizing treatment burden are more important than tight glycemic control in older adults. [American Diabetes Association] [4][5][6][7]

Metformin ER 1000 mg once daily is bioequivalent to metformin immediate‑release 1000 mg twice daily and is associated with fewer gastrointestinal adverse effects. [American Diabetes Association] [1][2]
Switching to metformin ER directly addresses the adherence problem without adding another medication or increasing cost. [American Diabetes Association] [1][2]
Metformin remains the foundational glucose‑lowering agent, providing proven cardiovascular and mortality benefits. [American Diabetes Association] [1][2]3
Reassessment of A1C should be performed 3 months after the switch to evaluate the need for additional therapy. [American Diabetes Association] [1][2]

If A1C remains ≥ 1.5 % above the individualized goal (i.e., > 8.0 %) after optimizing metformin adherence, dual therapy with empagliflozin is indicated. [American Diabetes Association] [1][2]3
Adding empagliflozin before confirming adequate metformin adherence may be premature, as poor control often stems from missed doses rather than insufficient drug potency. [American Diabetes Association] [1][2]
Polypharmacy concerns favor a stepwise approach; simplifying the regimen with metformin ER alone may achieve targets without a second agent. [American Diabetes Association] [4][5][6][7]
Generic metformin ER is inexpensive, whereas combination products such as Synjardy XR may face cost and insurance barriers. [American Diabetes Association] [1][2]

Step	Action	Rationale / Evidence
1	Switch metformin IR 1000 mg BID to metformin ER 1000 mg once daily (taken with evening meal).	Improves adherence; bioequivalent efficacy. [1][2]
2	Reassess A1C after 3 months.	Determines need for escalation. [1][2]
3	If A1C < 8.0 % – continue metformin ER alone; monitor every 6 months.	Target achieved with simplified regimen. [1][2]
4	If A1C ≥ 8.0 % – check eGFR; add empagliflozin 10 mg once daily or switch to Synjardy XR 5/1000 mg once daily.	Dual therapy indicated when target not met. [3]
5	Monitor for volume depletion, urinary‑tract infection, and genital mycotic infection after starting empagliflozin.	Safety monitoring in older adults. [3]
6	Reassess A1C 3 months after adding empagliflozin.	Evaluate response to second agent. [1][2]
7	If A1C > 8.0 % despite dual therapy – consider adding a GLP‑1 receptor agonist or basal insulin based on comorbidities and patient preference.	Escalation for persistent hyperglycemia. [1][2][3]

Initiate treatment with metformin ER 1000 mg once daily to resolve adherence issues. [American Diabetes Association] [1][2]
If A1C remains > 8.0 % after 3 months, add empagliflozin 10 mg once daily or transition to Synjardy XR 5/1000 mg once daily. [American Diabetes Association] 3
This stepwise, adherence‑centric approach prioritizes safety, quality of life, and avoidance of unnecessary polypharmacy. [American Diabetes Association] [4][5]6